Clinical and Genetic Characteristics of 10 Patients with IQSEC2-Related Encephalopathy: A Single-Center Cohort Study

Article information

Ann Child Neurol. 2026;34(4):297-304
Publication date (electronic) : 2026 October 1
doi : https://doi.org/10.26815/acn.2026.01536
1Department of Pediatric Neurology, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea
2Division of Pediatric Neurology, Hanim Precision Medical Center, Epilepsy Research Institute, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
3Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
Corresponding authors: Ara Ko, MD, PhD Department of Pediatric Neurology, Severance Children’s Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-1004 Fax: +82-2-393-9118 E-mail: arako@yuhs.ac
Hoon-Chul Kang, MD, PhD Department of Pediatric Neurology, Severance Children’s Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-1004 Fax: +82-2-393-9118 E-mail: hipo0207@yuhs.ac
Received 2026 April 3; Revised 2026 July 12; Accepted 2026 July 21.

Abstract

Purpose

IQ motif and Sec7 domain ArfGEF 2 (IQSEC2)-related encephalopathy is a rare neurodevelopmental disorder characterized by developmental impairment, epilepsy, and behavioral abnormalities. This study investigated the clinical and genetic features of 10 patients with IQSEC2-related encephalopathy treated at a single center in Korea.

Methods

We retrospectively reviewed the medical records of 10 patients with pathogenic or likely pathogenic IQSEC2 variants. Clinical characteristics, epilepsy phenotypes, neurodevelopmental features, neuroimaging findings, and genetic data were analyzed.

Results

The cohort included four males and six females, and four variants were novel. The identified variants comprised four nonsense variants, three frameshift variants, one missense variant, one splice-site variant, and one exon deletion. Epilepsy was documented in nine patients, including Lennox–Gastaut syndrome in four, Doose syndrome in one, and nonspecific epilepsy in four; the mean age at seizure onset was 2.4 years. All patients had developmental delay ranging from mild to severe, and developmental delay had been recognized before seizure onset in nine patients. Autism spectrum disorder was documented in four patients, brain magnetic resonance imaging abnormalities in five, scoliosis in four, and precocious puberty in two.

Conclusion

IQSEC2-related encephalopathy showed a heterogeneous clinical spectrum that included epilepsy, developmental impairment, and variable behavioral and systemic features. The identification of precocious puberty in two patients expands the reported clinical spectrum. Central precocious puberty has rarely been described in patients with IQSEC2-related encephalopathy. Although a direct causal relationship remains unclear, these findings support the need for endocrine surveillance as part of longitudinal care.

Introduction

IQ motif and Sec7 domain ArfGEF 2 (IQSEC2) is located on the X-chromosome and encodes a guanine nucleotide exchange factor involved in excitatory synaptic function [1]. Pathogenic IQSEC2 variants are associated with a neurodevelopmental disorder characterized by developmental delay, intellectual disability, epilepsy, and behavioral abnormalities in both males and females [2,3]. Experimental and translational studies suggest that IQSEC2 dysfunction may alter synaptic transmission, increase neuronal hyperexcitability, and disrupt excitatory–inhibitory network balance [1,4,5]. Although IQSEC2-related encephalopathy is increasingly recognized, its clinical spectrum remains incompletely characterized because the disorder is rare and marked phenotypic variability has been reported across affected individuals [2,6-10]. In this study, we describe the clinical phenotypes and genetic characteristics of 10 patients with IQSEC2-related encephalopathy identified at a single center in Korea.

Materials and Methods

1. Patients and clinical data

We retrospectively reviewed the medical records of patients with IQSEC2 variants identified at Severance Hospital between January 2014 and October 2025. Demographic, clinical, electroencephalographic, neuroimaging, treatment, and genetic data were extracted from the medical records. Developmental severity at the last evaluation was classified as mild, moderate, or severe on the basis of available standardized developmental or cognitive assessments, including intelligence quotient or developmental quotient scores when available, together with functional information documented in the medical records. Domain-specific developmental profiles are provided in Supplementary Table 1.

2. Genetic testing and variant interpretation

IQSEC2 variants were identified using a customized 172-gene panel for epilepsy and developmental and epileptic encephalopathy, as previously described [11,12]. Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp Blood DNA Mini Kit (Qiagen, Hilden, Germany). DNA was quantified using the Qubit HS dsDNA kit (Invitrogen, Carlsbad, CA, USA), and sequencing was performed using a MiSeq sequencer (Illumina, San Diego, CA, USA). Sequencing data were aligned to the GRCh37/hg19 reference genome. Single-nucleotide variants and small insertions or deletions were detected using an in-house variant-calling pipeline, and copy-number variants, including exon-level deletions and duplications, were analyzed using ExomeDepth. Larger deletions or duplications were confirmed by additional methods when required. Variant analysis was limited to protein-coding regions and canonical splice-site regions, and variants with low mapping quality or insufficient coverage were excluded.

Variants were annotated and reviewed using public and disease-specific databases, including ClinVar, dbSNP, the 1000 Genomes Project, the Genome Aggregation Database (gnomAD), the Exome Aggregation Consortium (ExAC), the Exome Sequencing Project, the Korean Reference Genome Database (KRGDB), the Leiden Open Variation Database, and Online Mendelian Inheritance in Man [11,12]. Inheritance was recorded as unknown when parental samples were unavailable or segregation testing was not performed, and de novo status was confirmed by parental testing when available. In silico prediction was applied when appropriate: Combined Annotation Dependent Depletion (CADD) was used for the missense variant, and the online SpliceAI server was used to assess the potential splicing effect of intronic or splice-region variants. Variant nomenclature followed Human Genome Variation Society recommendations, and sequence variants were described according to the IQSEC2 reference transcript NM_001111125.2. Variants were classified according to the standards and guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology [13]. Interpretation was based on population frequency, in silico prediction, ClinVar annotation, published data, genotype–phenotype correlation, family studies, and confirmatory assays. When further clinical correlation was required, genotype–phenotype correlations were reviewed in consensus discussions among geneticists, pediatric neurologists, and laboratory diagnosticians, together with additional family studies or confirmatory assays. A variant was considered novel if it had not been reported in the literature and was absent from, or had not previously been classified in, public databases at the time of review. Confirmatory Sanger sequencing was performed when clinically indicated.

This study was approved by the Institutional Review Board of Severance Hospital (IRB No. 2026-0180-001). The requirement for informed consent was waived because this retrospective study used de-identified clinical data.

Results

Clinical and genetic data were collected from 10 previously unreported patients with IQSEC2 variants, including four males and six females. Four variants were novel. The identified variants comprised four nonsense variants, three frameshift variants, one missense variant, one splice-site variant, and one exon deletion (Table 1) [12,14-16]. No population frequency was identified for the sequence variants in gnomAD, ExAC, or KRGDB at the time of variant interpretation. Because the exact breakpoints of the exon 8 deletion were unavailable, its reading-frame consequence, precise breakpoint-level population frequency, and precise functional domain affected could not be determined. The distribution of variants across the IQSEC2 protein is shown in Fig. 1. According to the American College of Medical Genetics and Genomics/Association for Molecular Pathology classification, one variant was classified as pathogenic and nine as likely pathogenic.

Genetic findings and ACMG classification of the identified IQSEC2 variants

Fig. 1.

Distribution of IQ motif and Sec7 domain ArfGEF 2 (IQSEC2) variants identified in this cohort. Variants from patients P1–P9 are mapped to the IQSEC2 protein structure. Major functional domains are indicated. Patient 10 is not shown because the exact breakpoint of the copy-number deletion was unavailable. CC, coiled-coil domain; IQ, isoleucine-glutamine calmodulin-binding motif; Sec7, Sec7 guanine nucleotide exchange factor domain; PH, pleckstrin homology domain; PDZ, postsynaptic density protein 95/discs large/zonula occludens-1-binding motif; P, patient. aNovel variants.

Clinical characteristics are summarized in Table 2. Epilepsy was documented in nine of the 10 patients, and epilepsy phenotypes were heterogeneous. Patients were categorized as having Lennox–Gastaut syndrome (LGS; n=4), Doose syndrome (n=1), or nonspecific epilepsy (n=4), including one patient whose epilepsy evolved from infantile epileptic spasms syndrome (IESS) to LGS (patient 1). Seizure semiology included generalized tonic seizures, epileptic spasms, myoclonic/atonic seizures, absence seizures, and focal seizures; electroencephalography commonly showed a slow background with multifocal or generalized epileptiform discharges. The mean age at seizure onset was 2.4 years, and one patient developed seizures before 1 year of age. Status epilepticus was reported in one patient (patient 4). Most patients required polytherapy during the disease course. Ketogenic diet therapy was used in patients with more refractory epilepsy, and reduced seizure frequency was observed in three of the four treated patients. At the last follow-up, two patients had been seizure-free for at least 3 months, indicating that seizure control was achievable in some patients despite the frequent need for polytherapy. Steroid therapy was administered in one patient and was associated with an approximately 50% reduction in seizure frequency; however, it was discontinued after short-term use because seizures persisted. No patient underwent surgery for seizure control.

Clinical characteristics of the 10 patients with IQSEC2-related encephalopathy

Developmental and cognitive assessments included the Korean Wechsler Intelligence Scale for Children (K-WISC), Korean Wechsler Preschool and Primary Scale of Intelligence (K-WPPSI), K-WPPSI-IV, Bayley Scales of Infant and Toddler Development-II/III, and Denver developmental assessment, depending on patient age and available clinical records. All patients had developmental delay ranging from mild to severe, and developmental delay had been recognized before seizure onset in nine patients. Developmental outcome at the last evaluation was classified as mild in two patients, moderate in five, and severe in three. Two patients were unable to walk independently, whereas the remaining eight achieved independent walking. Autism spectrum disorder (ASD) was documented in four patients. Domain-specific developmental profiles are provided in Supplementary Table 1. One male patient (patient 10) had a history of perinatal asphyxia and had been diagnosed with cerebral palsy after birth.

Brain magnetic resonance imaging (MRI) findings were normal in five patients and abnormal in five. Reported abnormalities included decreased brain volume, frontal lobe volume reduction, corpus callosum thinning, mild frontoparietal atrophic change, and unilateral peritrigonal white matter volume loss with ventricular asymmetry. Additional clinical features included scoliosis in four patients, including one patient (patient 2) who required surgery. Precocious puberty and ophthalmologic abnormalities were each documented in two patients.

Discussion

The clinical course of IQSEC2-related encephalopathy remains insufficiently characterized. In this cohort of 10 patients, IQSEC2-related encephalopathy showed a broad clinical spectrum that included developmental delay or intellectual disability, epilepsy, and variable behavioral features. Overall, the clinical features in this cohort were similar to those reported in previous cohort studies. This study adds clinical information on epilepsy trajectories, developmental course before seizure onset, and associated comorbidities [2,6-8].

Epilepsy was documented in nine of 10 patients, but the phenotype was heterogeneous and did not follow a single electroclinical pattern, consistent with prior epilepsy-focused studies [9,10]. In this cohort, epilepsy classifications included developmental and epileptic encephalopathy patterns, with LGS in multiple patients and evolution from IESS to LGS in one patient; other patients were classified as having nonspecific epilepsy or Doose syndrome. These findings support approaching IQSEC2-related epilepsy as a spectrum rather than as a syndrome with a predictable trajectory.

Although seizure onset in IQSEC2-related encephalopathy has been reported to occur mainly after the first year of life, this cohort included one patient with seizure onset before 1 year of age and another with status epilepticus [10]. These findings suggest that early-onset seizures and severe acute exacerbations can occur in IQSEC2-related encephalopathy, although they may not represent the predominant epilepsy presentation. This observation may be useful when IQSEC2-related encephalopathy is considered in patients with early-onset seizures accompanied by developmental impairment.

Treatment response was variable, and several patients required multiple antiseizure medications, consistent with the previously reported tendency toward difficult-to-control seizures [9,10]. Ketogenic diet therapy was attempted in four patients, and seizure reduction was observed in three, suggesting that dietary therapy may be considered as an adjunctive option in selected refractory cases. Given the retrospective design and small sample size, this finding should be interpreted as a clinical signal rather than as comparative evidence.

Neurodevelopmental impairment was consistent across the cohort, with all patients showing developmental delay or intellectual disability ranging from mild to severe. Developmental delay was recognized before seizure onset in most patients, supporting the concept that neurodevelopmental impairment in IQSEC2-related encephalopathy is not solely driven by epilepsy burden. This finding is consistent with prior observations that developmental delay often precedes epilepsy onset and that age at seizure onset is not consistently correlated with developmental severity [2,4,6,10]. Experimental studies using patient-derived neurons have suggested early neuronal hyperexcitability followed by impaired synaptic transmission during maturation, which may help explain neurodevelopmental impairment that is not entirely dependent on seizure burden [4].

Clinically, these findings emphasize the need for early developmental evaluation and intervention alongside seizure management, rather than assuming that developmental outcomes depend primarily on seizure control. Behavioral abnormalities, including ASD documented in a subset of patients, were also consistent with previously described neurobehavioral manifestations, such as autistic traits, stereotypies, and behavioral disturbances [7,17].

Phenotypic differences between males and females have been recognized in IQSEC2-related encephalopathy and may be partly explained by the location of IQSEC2 on the X-chromosome and its reported escape from X-chromosome inactivation [2,18]. Previous studies have suggested that affected males tend to have more severe developmental impairment, earlier seizure onset, and more refractory epilepsy than affected females [2,18]. In this cohort, the only patient without epilepsy was female, which is broadly compatible with this reported pattern. However, no obvious sex-related difference in age at seizure onset was observed. Because the sample size was small, this observation should be interpreted cautiously and should not be considered evidence against previously reported sex-related differences.

The variants identified in this cohort were distributed across multiple regions of IQSEC2, and most were truncating variants, including nonsense, frameshift, splice-site, or deletion variants, consistent with previously reported mutation spectra [2,19]. No clear genotype–phenotype relationship was identified on the basis of variant class alone. This finding is consistent with prior studies suggesting that clinical severity is not explained simply by a truncating-versus-missense distinction and may reflect additional modifiers, such as variant location, sex, or other genetic and environmental factors [2,18,19]. The identification of four novel variants expands the reported molecular spectrum of IQSEC2-related encephalopathy.

Brain MRI was abnormal in approximately half of the patients in this cohort, with findings such as decreased brain volume, corpus callosum thinning, and focal white matter volume loss. These findings are consistent with the view that neuroimaging findings in IQSEC2-related disorders can be variable and nonspecific [2,7,8]. Systemic comorbidities that may affect longitudinal care were also observed. Scoliosis was present in multiple patients, including one who required surgery, suggesting that orthopedic surveillance and timely referral may be clinically relevant for some individuals with IQSEC2-related encephalopathy. In addition, precocious puberty was documented in two patients. Endocrine manifestations have rarely been emphasized in the IQSEC2 literature, although earlier age at menarche was recently reported in an Italian national structured survey [6]. Whereas that study suggested a potential association on the basis of registry-based survey data, the present study provides additional detailed clinical descriptions of central precocious puberty in patients with IQSEC2 variants. Although a definitive causal relationship between endocrine abnormalities and IQSEC2 variants remains unclear, this finding supports comprehensive endocrine surveillance during longitudinal care.

This study has several limitations. The small cohort size, which reflects the rarity of IQSEC2-related encephalopathy, limited robust statistical analysis and formal evaluation of sex differences, treatment effectiveness, and genotype–phenotype correlations. For the exon 8 deletion, the exact breakpoints were unavailable, limiting assessment of its reading-frame consequence, precise affected functional domain, and breakpoint-level population frequency. The retrospective, single-center design may have introduced selection bias toward more severely affected patients and limits the generalizability of the findings. In addition, some clinical features may have been underascertained because documentation was not standardized and formal neuropsychological testing was variably available. Sex-related phenotypic comparisons should therefore be interpreted cautiously, and the endocrine findings observed in a subset of patients should be considered exploratory until they are validated in larger cohorts. Despite these limitations, this cohort provides detailed clinical data from an underrepresented population and contributes novel variants to the expanding literature on IQSEC2.

In conclusion, IQSEC2-related encephalopathy in this cohort showed marked clinical heterogeneity, encompassing epilepsy, neurodevelopmental impairment, and variable behavioral and systemic manifestations. Developmental delay frequently preceded seizure onset, suggesting that neurodevelopmental impairment in IQSEC2-related encephalopathy may not be solely attributable to epileptic activity. Epilepsy phenotypes were diverse, ranging from LGS to other developmental and epileptic encephalopathy patterns. Ketogenic diet therapy may be considered in selected patients with refractory epilepsy, although further evidence is needed. Further multicenter longitudinal studies are warranted to delineate the natural history, identify modifiers of disease severity, and guide management strategies for this rare disorder.

Supplementary material

Supplementary materials related to this article can be found online at https://doi.org/10.26815/acn.2026.01536.

Supplementary Table 1.

Developmental profiles of patients with IQSEC2-related encephalopathy

acn-2026-01536-Supplementary-Table-1.pdf

Notes

Conflicts of interest

Hoon-Chul Kang is an associate editor, Se Hee Kim and Ara Ko are managing editors, Joon Soo Lee is an editorial board member of the journal, but they were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Author contribution

Conceptualization: SL, SHK, JSL, and HCK. Data curation: KL and HCK. Formal analysis: KL. Funding acquisition: KL. Visualization: AK. Writing - original draft: KL. Writing - review & editing: AK.

Acknowledgments

The authors thank the patients and their families for participating in this study.

References

1. Levy NS, Umanah GK, Rogers EJ, Jada R, Lache O, Levy AP. IQSEC2-associated intellectual disability and autism. Int J Mol Sci 2019;20:3038. 10.3390/ijms20123038. 31234416.
2. Mignot C, McMahon AC, Bar C, Campeau PM, Davidson C, Buratti J, et al. IQSEC2-related encephalopathy in males and females: a comparative study including 37 novel patients. Genet Med 2019;21:837–49. 10.1038/s41436-018-0268-1. 30206421.
3. Jackson MR, Loring KE, Homan CC, Thai MHN, Maattanen L, Arvio M, et al. Heterozygous loss of function of IQSEC2/Iqsec2 leads to increased activated Arf6 and severe neurocognitive seizure phenotype in females. Life Sci Alliance 2019;2e201900386. 10.26508/lsa.201900386. 31439632.
4. Brant B, Stern T, Shekhidem HA, Mizrahi L, Rosh I, Stern Y, et al. IQSEC2 mutation associated with epilepsy, intellectual disability, and autism results in hyperexcitability of patient-derived neurons and deficient synaptic transmission. Mol Psychiatry 2021;26:7498–508. 10.1038/s41380-021-01281-0. 34535765.
5. Mehta A, Shirai Y, Kouyama-Suzuki E, Zhou M, Yoshizawa T, Yanagawa T, et al. IQSEC2 deficiency results in abnormal social behaviors relevant to autism by affecting functions of neural circuits in the medial prefrontal cortex. Cells 2021;10:2724. 10.3390/cells10102724. 34685703.
6. Leoncini S, Boasiako L, Lopergolo D, Altamura M, Fazzi C, Canitano R, et al. Natural course of IQSEC2-related encephalopathy: an Italian national structured survey. Children (Basel) 2023;10:1442. 10.3390/children10091442. 37761403.
7. Radley JA, O'Sullivan RB, Turton SE, Cox H, Vogt J, Morton J, et al. Deep phenotyping of 14 new patients with IQSEC2 variants, including monozygotic twins of discordant phenotype. Clin Genet 2019;95:496–506. 10.1111/cge.13507. 30666632.
8. Tran Mau-Them F, Willems M, Albrecht B, Sanchez E, Puechberty J, Endele S, et al. Expanding the phenotype of IQSEC2 mutations: truncating mutations in severe intellectual disability. Eur J Hum Genet 2014;22:289–92. 10.1038/ejhg.2013.113. 23674175.
9. Zerem A, Haginoya K, Lev D, Blumkin L, Kivity S, Linder I, et al. The molecular and phenotypic spectrum of IQSEC2-related epilepsy. Epilepsia 2016;57:1858–69. 10.1111/epi.13560. 27665735.
10. Mastrangelo M, Greco C, Tolve M, Bartolini E, Russo A, Nicita F, et al. Epilepsy phenotypes across the different age-ranges in IQSEC2-related encephalopathy: an Italian multicentre retrospective cohort study. Seizure 2024;119:119–27. 10.1016/j.seizure.2024.06.002. 38851096.
11. Shin HJ, Ko A, Kim SH, Lee JS, Kang HC. Unusual voltage-gated sodium and potassium channelopathies related to epilepsy. J Clin Neurol 2024;20:402–11. 10.3988/jcn.2023.0435. 38951973.
12. Kim SH, Kwon SS, Lee JS, Kim HD, Lee ST, Choi JR, et al. Analysis of trio test in neurodevelopmental disorders. Front Pediatr 2022;10:1073083. 10.3389/fped.2022.1073083. 36619507.
13. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24. 10.1038/gim.2015.30. 25741868.
14. Epi4K Consortium; Epilepsy Phenome/Genome Project, Allen AS, Berkovic SF, Cossette P, Delanty N, et al. De novo mutations in epileptic encephalopathies. Nature 2013;501:217–21. 10.1038/nature12439. 23934111.
15. Allou L, Julia S, Amsallem D, El Chehadeh S, Lambert L, Thevenon J, et al. Rett-like phenotypes: expanding the genetic heterogeneity to the KCNA2 gene and first familial case of CDKL5-related disease. Clin Genet 2017;91:431–40. 10.1111/cge.12784. 27062609.
16. Shoubridge C, Walikonis RS, Gecz J, Harvey RJ. Subtle functional defects in the Arf-specific guanine nucleotide exchange factor IQSEC2 cause non-syndromic X-linked intellectual disability. Small GTPases 2010;1:98–103. 10.4161/sgtp.1.2.13285. 21686261.
17. Lopergolo D, Privitera F, Castello G, Lo Rizzo C, Mencarelli MA, Pinto AM, et al. IQSEC2 disorder: a new disease entity or a Rett spectrum continuum? Clin Genet 2021;99:462–74. 10.1111/cge.13908. 33368194.
18. Shoubridge C, Dudding-Byth T, Pasquier L, Goel H, Yap P, McConnell V. IQSEC2-related encephalopathy in males due to missense variants in the pleckstrin homology domain. Clin Genet 2022;102:72–7. 10.1111/cge.14136. 35347702.
19. Liu X, Zhang S, Wan L, Zhang X, Wang H, Zhang H, et al. IQSEC2-related encephalopathy in male children: novel mutations and phenotypes. Front Mol Neurosci 2022;15:984776. 10.3389/fnmol.2022.984776. 36267700.

Article information Continued

Fig. 1.

Distribution of IQ motif and Sec7 domain ArfGEF 2 (IQSEC2) variants identified in this cohort. Variants from patients P1–P9 are mapped to the IQSEC2 protein structure. Major functional domains are indicated. Patient 10 is not shown because the exact breakpoint of the copy-number deletion was unavailable. CC, coiled-coil domain; IQ, isoleucine-glutamine calmodulin-binding motif; Sec7, Sec7 guanine nucleotide exchange factor domain; PH, pleckstrin homology domain; PDZ, postsynaptic density protein 95/discs large/zonula occludens-1-binding motif; P, patient. aNovel variants.

Table 1.

Genetic findings and ACMG classification of the identified IQSEC2 variants

Patient Nucleotide change Amino acid change Variant type Inheritance ClinVar ACMG classification ACMG criteria Novelty/Reference Domain
1 c.224delA p.Asp75AlafsTer131 Frameshift Unknown Not reported LP PVS1 PM2 Novel N-terminal region
2 c.3322C>T p.Gln1108Ter Nonsense Unknown Not reported LP PVS1 PM2 Previously reported [14] C-terminal region
3 c.2577_2580delCTTC p.Phe860ProfsTer46 Frameshift Unknown Not reported LP PVS1 PM2 Novel Sec7 domain
4 c.2776C>T p.Arg926Ter Nonsense Unknown P LP PVS1 PM2 Previously reported [15] Sec7 domain
5 c.136G>T p.Glu46Ter Nonsense Unknown Not reported LP PVS1 PM2 Novel CC/N-terminal region
6 c.4325del p.Pro1442HisfsTer53 Frameshift De novo P/LP LP PVS1 PS2 PM2 ClinVar reported C-terminal region
7 c.2710C>T p.Arg904Ter Nonsense De novo Pathogenic P PVS1 PS2 PM2 Previously reported [16] Sec7 domain
8 c.2680G>A p.Asp894Asna Missense De novo VUS LP PS2 PM2 PP3 (CADD PHRED: 31) ClinVar reported Sec7 domain
9 c.3016-1G>T NA Splice-site variant De novo P LP PVS1 PM2 PS2 PP3 Previously reported [12] PH-adjacent region
10 exon 8 deletionb NA Deletion Unknown Not reported LP PVS1 PM2 Novel Not determined

For truncating variants with unknown inheritance, de novo evidence was not applied; classification as likely pathogenic was based on PVS1 and PM2, reflecting predicted loss of function in IQSEC2 and absence from population databases.

ACMG, American College of Medical Genetics and Genomics; IQSEC2, IQ motif and Sec7 domain ArfGEF 2; LP, likely pathogenic; PVS1, pathogenic very strong criterion 1; PM2, pathogenic moderate criterion 2; P, pathogenic; CC, coiled-coil domain; PS2, pathogenic strong criterion 2; VUS, variant of uncertain significance; PP3, pathogenic supporting criterion 3; CADD PHRED, Phred-scaled Combined Annotation Dependent Depletion score; NA, not available; PH, pleckstrin homology domain.

a

The p.Asp894Asn variant is listed as a variant of uncertain significance in ClinVar. In this study, it was classified as likely pathogenic based on confirmed de novo occurrence in the affected patient (PS2, strong), absence from population databases (PM2), and deleterious in silico prediction with a CADD PHRED score of 31 (PP3). The patient’s phenotype was consistent with IQSEC2-related encephalopathy and was considered in the overall interpretation;

b

For the exon 8 deletion, the exact genomic breakpoints were unavailable; therefore, its reading-frame consequence, precise affected functional domain, and breakpoint-level population frequency could not be assessed.

Table 2.

Clinical characteristics of the 10 patients with IQSEC2-related encephalopathy

Patient Sex Perinatal asphyxia Age at seizure onset (yr) Age at last follow-up (yr) Epilepsy SE Seizure semiology EEG findings Epilepsy syndrome/classification Seizure frequency at last follow-up Current ASMs Effective ASMs Ineffective ASMs Other treatment Brain MRI findings Development before seizure onset Cognitive assessment, score (age at test) Neurodevelopmental outcome Independent walking Autism spectrum disorder Scoliosis Other comorbidities
1 F No 1.3 20 Yes No GT, ES SDBG, focal sharp IESS > LGS Seizure-free for 3 mo PER, CLB, LTG PER, CLB VGB No Diffuse volume loss with decreased thickness of the anterior body of the corpus callosum Delayed FSIQ <25 (6 yr 2 mo) Severe ID Able No Yes Epiblepharon, congenital exotropia
2 M No 0.5 16 Yes No GT, ES, Ms SDBG, multifocal sharp, GFSW, GSSW LGS 2-3/day VPA, LCS, ZNS NA NA KD, no meaningful seizure reduction Diffuse volume loss Delayed FSIQ 47 (6 yr 11 mo) Moderate ID Unable No Yes NA
3 F No 1 11 Yes No FBTC, GTC SDBG, multifocal sharp NS Seizure-free for 6 mo VPA, LEV LEV NA No Normal Delayed FSIQ 54 (3 yr 10 mo) Moderate ID Able Yes Yes Precocious puberty
4 F No 3.3 8 Yes Yes FIAS SDBG, rare focal sharp NS 3-4/day VPA, TPM, DZP DZP RFN No Normal Delayed NA Moderate ID Able Yes No NA
5 F No 4.9 5 Yes No M-At SDBG, generalized sharp Doose syndrome 10/day CLB, VPA, LTG, LEV NA NA KD, seizure reduction observed Normal Delayed NA Moderate ID Able Unknown Yes NA
6 M No 6.4 8 Yes No AS SDBG, multifocal sharp NS 3-4/day LEV, VPA NA NA No Mild right peritrigonal white matter volume loss with asymmetric enlargement of the right lateral ventricle Delayed Bayley MDI <50 (3 yr 9 mo) Severe ID Able Yes No ADHD, infantile esotropia, plagiocephaly
7 F No 1.2 4 Yes No GT, AS, M-At SDBG, multifocal sharp, GSW, GPFA LGS 10/day VPA, LEV, TPM, PB NA NA KD, seizure reduction observed Normal Delayed Bayley 55 (1 yr 6 mo) GDD Able Unknown No Primary hypothyroidism
8 F No N/A 6 No No N/A N/A N/A N/A N/A N/A N/A N/A Normal NA FSIQ 41 (5 yr 11 mo) Moderate ID Able No No NA
9 M No 1.7 5 Yes No Ab, Ms SDBG, focal sharp, generalized sharp, GPFA, GSSW LGS 2-3/week CLB, VPA VPA NA KD, seizure reduction observed Diffuse volume loss Delayed Bayley 55 (2 yr 2 mo) GDD Unable Yes No Precocious puberty, strabismus
10 M Yes 1.6 20 Yes No GT, Ms, Ab SDBG, generalized sharp, multifocal sharp, GPFA LGS 10/day TPM, CLB, LTG, VPA NA NA No Diffuse volume loss Delayed NA Severe ID Able Unknown No NA

Seizure-related variables were recorded as not applicable in the patient without epilepsy.

IQSEC2, IQ motif and Sec7 domain ArfGEF 2; SE, status epilepticus; EEG, electroencephalography; ASM, antiseizure medication; MRI, magnetic resonance imaging; GT, generalized tonic seizure; ES, epileptic spasms; SDBG, slow background; IESS, infantile epileptic spasms syndrome; LGS, Lennox–Gastaut syndrome; PER, perampanel; CLB, clobazam; LTG, lamotrigine; VGB, vigabatrin; FSIQ, full-scale intelligence quotient; ID, intellectual disability; Ms, myoclonic seizure; GFSW, generalized fast spike-and-wave; GSSW, generalized spike-and-slow-wave; VPA, valproic acid; LCS, lacosamide; ZNS, zonisamide; NA, not available; KD, ketogenic diet; FBTC, focal to bilateral tonic-clonic seizure; GTC, generalized tonic-clonic seizure; NS, nonspecific; LEV, levetiracetam; FIAS, focal impaired awareness seizure; TPM, topiramate; DZP, diazepam; RFN, rufinamide; M-At, myoclonic-atonic seizure; AS, atonic seizure; Bayley, Bayley Scales of Infant and Toddler Development; MDI, mental development index; ADHD, attention-deficit/hyperactivity disorder; GSW, generalized spike-and-wave; GPFA, generalized paroxysmal fast activity; PB, phenobarbital; GDD, global developmental delay; N/A, not applicable; Ab, absence seizure.